Opexa Therapeutics to Present at the 15th Annual BIO CEO & Investor
BIO CEO & Investor Conference 2013
THE WOODLANDS, Texas -- February 7, 2013
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tcelna™, a novel
T-cell therapy for multiple sclerosis (MS), today announced that Neil K.
Warma, President and Chief Executive Officer, will present at the 15^th Annual
BIO CEO & Investor Conference on Monday, February 11, 2013, at 2:30 p.m. EST
in the Conrad Room. The conference will be held at the Waldorf-Astoria Hotel
in New York, NY.
A live webcast of the company presentation can be accessed via the Investor
Relations section of the Company’s website at www.opexatherapeutics.com. An
archive of the webcast will be available on the Company's website until May
Opexa Therapeutics, Inc. is dedicated to the development of patient-specific
cellular therapies for the treatment of autoimmune diseases such as MS. The
Company’s leading therapy, Tcelna™, is a personalized cellular immunotherapy
treatment that is in late stage clinical development for MS. Tcelna is derived
from T-cells isolated from peripheral blood, expanded ex vivo, and
reintroduced into the patients via subcutaneous injections. This process
triggers a potent immune response against specific subsets of autoreactive
T-cells known to attack myelin and, thereby, reduces the risk of relapse over
About The BIO CEO & Investor Conference
The 15^th Annual BIO CEO & Investor Conference is the largest independent
investor conference focused on publicly-traded biotechnology companies. The
conference is designed to foster an informative dialogue between institutional
investors and senior biotechnology executives about emerging and current
For more information, please visit the Company’s website at
Opexa Therapeutics, Inc.
Neil K. Warma
President & CEO
The Trout Group
Press spacebar to pause and continue. Press esc to stop.